PGNY Q3 Deep Dive: Product Expansion and Client Diversification Drive Momentum

Fertility benefits company Progyny (NASDAQ:PGNY) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 9.3% year on year to $313.3 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $300.2 million was less impressive, coming in 0.7% below expectations. Its non-GAAP profit of $0.45 per share was 15.4% above analysts’ consensus estimates.

Is now the time to buy PGNY? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Progyny’s third quarter was marked by strong top-line and profitability outperformance, which drew a positive market response. Management attributed these results to robust new client acquisition, the successful addition of over 80 new employer logos, and continued high member engagement. CEO Peter Anevski highlighted the company’s “continued execution” despite macroeconomic headwinds, emphasizing the near 100% renewal rate among existing clients as a critical sign of their market position. The diversification of Progyny’s client base across industries and the growth in covered lives were also called out as essential contributors.

Looking forward, Progyny’s guidance is anchored by expanded benefit offerings and a broader addressable market, particularly with the launch of a new supplemental plan targeting small and midsized businesses. Management expects ongoing demand for family building and women’s health services from both new and existing clients, alongside adoption of new products in areas like menopause and postpartum support. Anevski stated that the company is “well positioned to continue our growth trajectory into the next year and beyond,” while CFO Mark Livingston noted that disciplined investment in platform expansion and acquisitions will remain a focus.

Key Insights from Management’s Remarks

Management identified new client wins, member engagement, and expanded offerings as primary drivers of the quarter’s results, while highlighting ongoing investments in product development and market reach.

• Client diversification broadens base: Progyny’s new client wins spanned a wide range of industries, including healthcare, tech, financial services, and education, reducing reliance on any single sector and mitigating concentration risk. This broader base supports more resilient revenue streams.
• Benefit expansion fuels retention: Nearly 30% of clients chose to increase their benefit coverage for 2026, with no significant reductions among existing clients. This expansion, including add-ons like postpartum and menopause support, contributed to the company’s near-perfect renewal rates.
• New product launches gain traction: The rollout of supplemental plans for small and midsized businesses, as well as the Progyny Global platform for multinational employers, marked significant steps in broadening the company’s market. Early feedback and uptake from clients were described as “incredibly positive.”
• Continued margin improvement: Operating margin improvements were driven by disciplined cost management and investments in technology and integration of recent acquisitions. The company also benefited from a $2 million reduction in expenses related to an employee retention credit.
• Share repurchase program announced: With a strong cash position and no outstanding debt, Progyny authorized a $200 million share repurchase program for the first time, reflecting confidence in their ability to invest in growth while returning capital to shareholders.

Drivers of Future Performance

Progyny’s forward outlook is shaped by the expansion of its product suite, deeper client relationships, and disciplined investment in growth initiatives.

• Supplemental plans target new markets: The company is launching covered solutions for small and midsized employers, expanding from its traditional large enterprise focus. Management expects this to unlock incremental growth from over 50 million potential covered lives, supporting long-term revenue expansion.
• Ongoing engagement and upsell: Management believes that more comprehensive offerings in women’s health and family building—such as menopause, postpartum, and international support—will increase upsell opportunities with current clients and improve retention, although this will require ongoing investment in sales and product teams.
• Macro and utilization variability: While management remains optimistic, they continue to factor in potential variability in member utilization and macroeconomic conditions. CFO Mark Livingston emphasized that guidance accounts for seasonal and year-to-year fluctuations in treatment rates, particularly around holidays and economic uncertainty.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the initial adoption and revenue contribution of the new supplemental plans for small and midsized employers, (2) the progress of Progyny Global in attracting multinational clients, and (3) the level of upsell activity among existing clients for expanded women’s health offerings. The pace of new client wins and integration of recent acquisitions will also be important indicators of execution.

Progyny currently trades at $21, up from $18.02 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

Now Could Be The Perfect Time To Invest In These Stocks

Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.

Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.